A 45-year-old woman from Mumbai is found to be HBsAg positive on routine blood donation screening. She is asymptomatic with normal liver function tests (ALT 32 IU/L). Serology shows: HBsAg positive, anti-HBc IgG positive, anti-HBc IgM negative, HBeAg negative, anti-HBe positive, HBV DNA 1.2 × 10⁶ copies/mL. What is the most appropriate next step in management?

Explanation

## Clinical Context: Chronic Hepatitis B Infection The serological profile is diagnostic of **chronic hepatitis B infection** (HBsAg positive >6 months): - **HBsAg positive**: Indicates chronic infection - **Anti-HBc IgG positive**: Indicates past/chronic infection (not acute) - **Anti-HBc IgM negative**: Rules out acute infection - **HBeAg negative, anti-HBe positive**: Indicates HBeAg-negative chronic HBV (lower replication state) - **HBV DNA 1.2 × 10⁶ copies/mL (≈ 200,000 IU/mL)**: Detectable viral load despite HBeAg negativity **Key Point:** HBeAg-negative chronic HBV with detectable HBV DNA and normal ALT does NOT automatically mean the patient needs immediate antiviral therapy. Careful risk stratification is required. ## Diagnostic Workup for Chronic HBV ### Step 1: Confirm Chronicity and Viral Load 1. Repeat HBV DNA (to confirm persistent viremia) 2. Repeat liver function tests and platelet count 3. Assess for cirrhosis risk using: - **Transient elastography (FibroScan)**: Non-invasive, measures liver stiffness - **Liver biopsy**: Gold standard if elastography unavailable or results equivocal - **Fibrosis-4 (FIB-4) index**: `$FIB-4 = \frac{Age \times AST}{Platelet\ count \times \sqrt{ALT}}$` (simple bedside calculation) ### Step 2: Assess HCC Risk - **Ultrasound abdomen** (baseline) - **AFP level** (baseline) - If cirrhosis detected: 6-monthly ultrasound + AFP surveillance ### Step 3: Determine Antiviral Therapy Eligibility | Parameter | HBeAg-Positive | HBeAg-Negative | |-----------|---|---| | **ALT threshold for treatment** | >1× ULN | >1× ULN | | **HBV DNA threshold for treatment** | >10⁵ IU/mL | >2000 IU/mL | | **Cirrhosis present?** | Treat if either threshold met | Treat if either threshold met | | **No cirrhosis, normal ALT** | Observe if HBV DNA <10⁵ | Observe if HBV DNA <2000 | **Clinical Pearl:** This patient has HBeAg-negative chronic HBV with HBV DNA 200,000 IU/mL (>2000 threshold) but normal ALT. She needs fibrosis assessment before deciding on antiviral therapy. If no cirrhosis and ALT persistently normal, observation with 6-monthly monitoring is acceptable; if cirrhosis or ALT rises, treatment is indicated. **High-Yield:** The 2023 AASLD/IDSA HBV Guidance emphasizes that **treatment decisions in HBeAg-negative HBV depend on BOTH HBV DNA level AND presence of cirrhosis**, not on HBsAg positivity alone. ## Why This Option Is Correct The next step is **risk stratification** (fibrosis assessment and repeat HBV DNA) to determine whether this patient meets criteria for antiviral therapy. Immediate treatment is not warranted without confirming cirrhosis or sustained ALT elevation.